Keywords: UCB,RESULTS, KEPPRA, CIMZIA, VIMPAT, NEUPRO

UCB heading for growth phase as new products drive 2012 sales

Article | 28 February 2013

Print This

UCB reported a 7 per cent rise in 2012 revenues to 3.46 billion euros ($4.54 billion) on the back ofstrong gains for rheumatoid arthritis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in